Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
about
Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cetuximab sensitivity of head ...... tion in EGFR, pEGFR, and pSrc.
@en
Cetuximab sensitivity of head ...... tion in EGFR, pEGFR, and pSrc.
@nl
type
label
Cetuximab sensitivity of head ...... tion in EGFR, pEGFR, and pSrc.
@en
Cetuximab sensitivity of head ...... tion in EGFR, pEGFR, and pSrc.
@nl
prefLabel
Cetuximab sensitivity of head ...... tion in EGFR, pEGFR, and pSrc.
@en
Cetuximab sensitivity of head ...... tion in EGFR, pEGFR, and pSrc.
@nl
P2093
P2860
P356
P1476
Cetuximab sensitivity of head ...... tion in EGFR, pEGFR, and pSrc.
@en
P2093
Adam Jedlinski
Ann-Charlotte Johansson
Karin Roberg
Per-Henrik Edqvist
Stina Garvin
P2860
P356
10.1111/JOP.12545
P577
2016-12-30T00:00:00Z